PharmaCyte Biotech, Inc.

- 07 JUN 2016
PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
SILVER SPRING, Md., June 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte’s therapies for cancer and diabetes at this year’s
Read more →
- Posted in
- News
- 03 JUN 2016
PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
SILVER SPRING, Md., June 03, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its entire senior management team will attend the American Society of Clinical Oncology’s (ASCO) 52nd annual meeting to
Read more →
- Posted in
- News
- 31 MAY 2016
PharmaCyte Biotech’s CEO Featured Speaker at Marcum MicroCap Conference
SILVER SPRING, Md., May 31, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th
Read more →
- Posted in
- News
- 26 MAY 2016
PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
SILVER SPRING, Md., May 26, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the Read more →
- Posted in
- News
- 24 MAY 2016
PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
SILVER SPRING, Md., May 24, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic
Read more →
- Posted in
- News
- 12 MAY 2016
PharmaCyte Biotech Receives ‘Notice of Allowance’ for Patent Protection of the Melligen Cells to Treat Diabetes
SILVER SPRING, Md., May 12, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of
Read more →
- Posted in
- News
- 03 MAY 2016
PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
SILVER SPRING, Md., May 03, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor. Dr. Sanjay Batra brings to PharmaCyte
Read more →
- Posted in
- News
- 25 APR 2016
PharmaCyte Biotech’s Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
SILVER SPRING, Md., April 25, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte’s biologic product under current Good
Read more →
- Posted in
- News
- 08 APR 2016
PharmaCyte Biotech’s Encapsulation Facility for Pancreatic Cancer Therapy Deemed Suitable by Thai FDA
SILVER SPRING, Md., April 08, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the encapsulation facility located in Bangkok, Thailand, that will be used to encapsulate the live cells used for
Read more →
- Posted in
- News
- 31 MAR 2016
PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration
SILVER SPRING, Md., March 31, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its live-cell encapsulation technology, Cell-in-a-Box®, today announced the final design of its clinical trial for patients with advanced pancreatic cancer. The clinical trial design was developed
Read more →
- Posted in
- News

Press Releases